Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer : a systematic review

Article Article scientifique Article Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer : a systematic review eng 2024-09-19 2024-09-19 author Kaufmann Ernest Department of Urology, University of Lucerne, Luzerner Kantonsspital, Spitalstrasse, 6000, 16, Lucerne, Switzerland. author Aeppli Stefanie Department of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland. author Arnold Winfried Department of Radiation-Oncology, Luzerner Kantonsspital, Lucerne, Switzerland. author Balermpas Panagiotis 0000-0001-5261-6446 Department of Radiation-Oncology, Universitiy Hospital Zurich, Zurich, Switzerland. author Beyer Jörg Department of Oncology, Inselspital Bern, Berne, Switzerland. author Bieri Uwe Department of Urology, Kantonsspital Baden, Baden, Switzerland.,Department of Urology, University Hospital Zurich, Zurich, Switzerland. author Cathomas Richard Department of Oncology, Kantonsspital Chur, Chur, Switzerland. author de Bari Berardino Department of Radiation-Oncology, Réseau Hospitalier Neuchâtelois, Neuchâtel, Switzerland. author Dressler Marco Zentrum Für Onkologie Luzern, Lucerne, Switzerland. author Engeler Daniel S Department of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland. author Erdmann Andreas Department of Oncology, Kantonsspital Baden, Baden, Switzerland. author Gallina Andrea Department of Urology, EOC Ente Ospedaliero Cantonale, Lugano, Switzerland. author Gomez Silvia Department of Radiation-Oncology, Kantonsspital Aarau, Aarau, Switzerland. author Guckenberger Matthias Department of Radiation-Oncology, Universitiy Hospital Zurich, Zurich, Switzerland. author Herrmann Thomas R W 0000-0003-4493-1301 Department of Urology, Spital Thurgau AG, Kantonsspital Frauenfeld, Frauenfeld, Switzerland.,Division of Urology, Department of Surgical Sciences, Stellenbosch University, Western Cape, South Africa.,Hannover Medical School, Hannover, Germany. author Hermanns Thomas Zentrum für Urologie Zürich, Zurich, Switzerland. author Ilaria Lucca Department of Urology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. author John Hubert Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. author Kessler Thomas M Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, Zurich, Switzerland. author Klein Jan Department of Urology, Kantonsspital Münsterlingen, Müsterlingen, Switzerland.,Department of Urology, Medical School, Ulm, Germany. author Laouiti Mohamed Department of Radiation-Oncology, Hôpital Riviera Chablais, Rennaz, Switzerland. author Lauffer David Cédric Department of Radiation-Oncology, University Hospital Geneva, Geneva, Switzerland. 887501 author Mattei Agostino Department of Urology, University of Lucerne, Luzerner Kantonsspital, Spitalstrasse, 6000, 16, Lucerne, Switzerland. author Müntener Michael Department of Urology, Stadtspital Triemli, Zurich, Switzerland. author Nguyen Daniel Department of Urology, Réseau Hospitalier Neuchâtelois, Neuchâtel, Switzerland. author Niederberger Philipp Department of Oncology, Luzerner Kantonsspital, Lucerne, Switzerland. author Papachristofilou Alexandros Department of Radiation-Oncology, University Hospital Basel, Basel, Switzerland. author Prause Lukas 0000-0002-1563-3543 Department of Urology, Kantonsspital Aarau, Aarau, Switzerland. author Reinhardt Karsten Department of Urology, St. Clara Hospital Basel, Basel, Switzerland. author Salati Emanuela Department of Oncology, Hôpital Riviera Chablais, Rennaz, Switzerland. author Sebe Philippe Department of Urology, University Hospital Geneva, Geneva, Switzerland. 416742 Département de chirurgie (CHIRU) author Shelan Mohamed 0000-0002-6477-6655 Department of Radiation-Oncology, Inselspital Bern, Berne, Switzerland. author Strebel Räto Department of Urology, Kantonsspital Chur, Chur, Switzerland. author Templeton Arnoud J Department of Oncology, St. Claraspital Basel and Faculty of Medicine, University Basel, Basel, Switzerland. author Vogl Ursula Department of Oncology, EOC Ente Ospedaliero Cantonale, Bellinzona, Switzerland. author Wettstein Marian S 0000-0003-1378-3625 Department of Uro-Oncology, University of Toronto, Toronto, Canada. author Zihler Deborah Department of Oncology, Kantonsspital Aarau, Aarau, Switzerland. author Zilli Thomas Department of Radiation-Oncology, EOC Ente Ospedaliero Cantonale, Bellinzona, Switzerland. author Zwahlen Daniel Department of Radiation-Oncology, Kantonsspital Winterthur, Winterthur, Switzerland. author Roth Beat Department of Urology, Inselspital Bern, Berne, Switzerland. author Fankhauser Christian 0000-0002-4073-5488 Department of Urology, University of Lucerne, Luzerner Kantonsspital, Spitalstrasse, 6000, 16, Lucerne, Switzerland. cdfankhauser@gmail.com. 527 10.1007/s00345-024-05196-7 39297968 0724-4983 PMC11413066 https://link.springer.com/10.1007/s00345-024-05196-7 Purpose: Optimal follow-up strategies following trimodal treatment for muscle invasive bladder cancer play a crucial role in detecting and managing relapse and side-effects. This article provides a comprehensive summary of the patterns and risk factors of relapse, functional outcomes, and follow-up protocols. Methods: A systematic literature search on PubMed and review of current guidelines and institutional follow-up protocols after trimodal therapy were conducted. Results: Out of 200 identified publications, 43 studies (28 retrospective, 15 prospective) were selected, encompassing 7447 patients (study sizes from 24 to 728 patients). Recurrence rates in the urinary bladder varied between 14-52%; 3-16% were muscle-invasive while 11-36% were non-muscle invasive. Nodal recurrence occurred at 13-16% and distant metastases at 15-35%. After 5 and 10 years of follow-up, around 60-85% and 45-75% of patients could preserve their bladder, respectively. Various prognostic risk factors associated with relapse and inferior survival were proposed, including higher disease stage (> c/pT2), presence of extensive/multifocal carcinoma in situ (CIS), hydronephrosis, multifocality, histological subtypes, incomplete transurethral resection of bladder tumor (TURBT) and incomplete response to radio-chemotherapy. The analyzed follow-up guidelines varied slightly in terms of the number, timing, and types of investigations, but overall, the recommendations were similar. Conclusion: Randomized prospective studies should focus on evaluating the impact of specific follow-up protocols on oncological and functional outcomes following trimodal treatment for muscle-invasive bladder cancer. It is crucial to evaluate personalized adaption of follow-up protocols based on established risk factors, as there is potential for improved patient outcomes and resource allocation. Bladder preservation Follow-up Functional outcomes Oncological outcomes Trimodal treatment Trimodality Dewey 616.0757 Dewey 617 62 Département de radiologie et informatique médicale 227 57 Département de chirurgie 222 false World journal of urology 42 1 a4d21a8f-c350-4fa8-bd7d-2dd6faf72bba Article (Published version) Public Article_scientifique_from_crossref.pdf 677964 application/pdf CC BY-4.0 c7ca44acd635c6856cb892a5500290441eb39448bd99db92716913a8c8e060a5 openAccess Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale Faculté de médecine / Section de médecine clinique / Département de chirurgie

Title	Published in	Year	Views	Downloads

Sarcomes des tissus mous : une approche nécessairement multidisciplinaire	Revue médicale suisse	2025	15	0
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer : a systematic review	World journal of urology	2024	13	49
Étude des paramètres cliniques et biologiques des patientes traitées par radiothérapie pour un cancer du sein droit		2020	504	517

Archive ouverte UNIGE

Lauffer, David Cédric